Terms: = Leukemia AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Treatment
105 results:
1. Systems Biology for Drug Target Discovery in Acute Myeloid leukemia.
Novikova S; Tolstova T; Kurbatov L; Farafonova T; Tikhonova O; Soloveva N; Rusanov A; Zgoda V
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731835
[TBL] [Abstract] [Full Text] [Related]
2. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and cdk6, shows strong anti-AML activity in defined preclinical models.
Yang T; Ke H; Liu J; An X; Xue J; Ning J; Hao F; Xiong L; Chen C; Wang Y; Zheng J; Gao B; Bao Z; Gong K; Zhang L; Zhang F; Guo S; Li QX
Sci Rep; 2024 Apr; 14(1):9032. PubMed ID: 38641704
[TBL] [Abstract] [Full Text] [Related]
3. Long noncoding RNA LINC00675 drives malignancy in acute myeloid leukemia via the miR-6809 -cdk6 axis.
Long X; Jiang H; Liu Z; Liu J; Hu R
Pathol Res Pract; 2024 Mar; 255():155221. PubMed ID: 38422911
[TBL] [Abstract] [Full Text] [Related]
4. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic leukemia.
Cruz-Miranda GM; Olarte-Carrillo I; Bárcenas-López DA; Martínez-Tovar A; Ramírez-Bello J; Ramos-Peñafiel CO; García-Laguna AI; Cerón-Maldonado R; May-Hau D; Jiménez-Morales S
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339034
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
6. 8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML treatment.
Wu PS; Wang CY; Hsu HJ; Yen JH; Wu MJ
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002257
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation.
Yu S; Zhang Y; Yang J; Xu H; Lan S; Zhao B; Luo M; Ma X; Zhang H; Wang S; Shen H; Zhang Y; Xu Y; Li R
Eur J Med Chem; 2024 Jan; 263():115924. PubMed ID: 37992518
[TBL] [Abstract] [Full Text] [Related]
8. Conferone, a coumarin from
Rafatpanah H; Golizadeh M; Mahdifar M; Mahdavi S; Iranshahi M; Rassouli FB
Int J Immunopathol Pharmacol; 2023; 37():3946320231197592. PubMed ID: 37688389
[TBL] [Abstract] [Full Text] [Related]
9. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J; Fiskus WC; Daver N; Wilson NR; Ravandi F; Garcia-Manero G; Kadia T; DiNardo CD; Jabbour E; Burger J; Short NJ; Alvarado Y; Jain N; Masarova L; Issa GC; Qiao W; Khoury JD; Pierce S; Miller D; Sasaki K; Konopleva M; Bhalla KN; Borthakur G; Pemmaraju N
Clin Cancer Res; 2023 Nov; 29(21):4352-4360. PubMed ID: 37585491
[TBL] [Abstract] [Full Text] [Related]
10. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Zhang C; Zhao X; Wang Z; Gong T; Zhao H; Zhang D; Niu Y; Li X; Zhao X; Li G; Dong X; Zhang L; Liu C; Xu J; Yu B
Invest New Drugs; 2023 Jun; 41(3):438-452. PubMed ID: 37097369
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic leukemia Cells.
Tian X; Zhu Z; Wang G; Xu J; Liang A; Zhang W
Dis Markers; 2022; 2022():9312971. PubMed ID: 35769815
[TBL] [Abstract] [Full Text] [Related]
12. Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Zhang MF; Luo XY; Zhang C; Wang C; Wu XS; Xiang QP; Xu Y; Zhang Y
Acta Pharmacol Sin; 2022 Oct; 43(10):2735-2748. PubMed ID: 35264812
[TBL] [Abstract] [Full Text] [Related]
13. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
[TBL] [Abstract] [Full Text] [Related]
14. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of Dual cdk6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the treatment of Acute Myeloid leukemia.
Yuan K; Ji M; Xie S; Qiu Z; Chen W; Min W; Xia F; Zheng M; Wang X; Li J; Hou Y; Kuang W; Wang L; Gu W; Li Z; Yang P
J Med Chem; 2022 Jan; 65(1):857-875. PubMed ID: 34958208
[TBL] [Abstract] [Full Text] [Related]
16. Genome-wide CRISPR screen identifies cdk6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T; Kumar S; Shimono J; Daenthanasanmak A; Dubois S; Lin Y; Bryant B; Petrus MN; Bachy E; Huang DW; Yang Y; Green PL; Hasegawa H; Maeda M; Goto H; Endo T; Yokota T; Hatanaka KC; Hatanaka Y; Tanaka S; Matsuno Y; Yang Y; Hashino S; Teshima T; Waldmann TA; Staudt LM; Nakagawa M
Blood; 2022 Mar; 139(10):1541-1556. PubMed ID: 34818414
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Aliagas E; Alay A; Martínez-Iniesta M; Hernández-Madrigal M; Cordero D; Gausachs M; Pros E; Saigí M; Busacca S; Sharkley AJ; Dawson A; Palmero R; Ruffinelli JC; Padrones S; Aso S; Escobar I; Ramos R; Llatjós R; Vidal A; Dorca E; Varela M; Sánchez-Céspedes M; Fennell D; Muñoz-Pinedo C; Villanueva A; Solé X; Nadal E
Br J Cancer; 2021 Nov; 125(10):1365-1376. PubMed ID: 34588615
[TBL] [Abstract] [Full Text] [Related]
18. Targeting the cdk6 Dependence of Ph+ Acute Lymphoblastic leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract] [Full Text] [Related]
19. Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols.
Rosati S; Gurnari C; Breccia M; Carmosino I; Scalzulli E; Montefusco E; Perrone S; Annibali O; Martini V; Trapè G; Colafigli G; Trawinska M; Minotti C; Cimino G; Tafuri A; Avvisati G; Martelli M; Voso MT; Latagliata R
Acta Oncol; 2021 Nov; 60(11):1520-1526. PubMed ID: 34461798
[TBL] [Abstract] [Full Text] [Related]
20. Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia.
Costa D; Granada I; Espinet B; Collado R; Ruiz-Xivillé N; Puiggros A; Uribe M; Arias A; Gómez C; Delgado J; Pereira A; Magnano L; Colomer D; López C; Beà S
Genes Chromosomes Cancer; 2022 Jan; 61(1):37-43. PubMed ID: 34414624
[TBL] [Abstract] [Full Text] [Related]
[Next]
